A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program
Sexual Health2007Vol. 4(3), pp. 165–175
Citations Over TimeTop 10% of 2007 papers
Shalini Kulasingam, Luke B. Connelly, Elizabeth L. Conway, Jane S. Hocking, Evan R. Myers, David G. Regan, David Roder, Jayne Ross, Gerard Wain
Abstract
These results suggest that adding an HPV vaccine to Australia's current screening regimen is a potentially cost-effective way to reduce cervical cancer and the clinical interventions that are currently associated with its prevention via screening alone.
Related Papers
- → Vaccination for COVID-19 control and considerations for Australia(2021)7 cited
- → Modeling COVID-19 vaccine efficacy and coverage towards herd-immunity in the Basque Country, Spain(2021)8 cited
- → Random network models to predict the long term impact of HPV vaccination on genital warts(2017)2 cited
- → Exploring Impacts to COVID-19 Herd Immunity Thresholds Under Demographic Heterogeneity that Lowers Vaccine Effectiveness(2022)1 cited
- → Exploring Impacts to COVID-19 Herd Immunity Thresholds Under Demographic Heterogeneity that Lowers Vaccine Effectiveness(2022)